MejorAsp

MejorAspTM PEG L – Asparaginase Injection 3750 IU/5ml

MejorAspTM_Package

Sayre Therapeutics offers clinicians a PEG L – Asparaginase formulation proven to be effective in Acute Lymphoblastic Leukemia (ALL)

  • Indication: MejorAsp ™ is indicated as a component of a multi agent chemotherapeutic regimen for the treatment of patients with Acute Lymphoblastic Leukemia who are hypersensitive to asparaginase.
  • Formulation: PEG L –Asparaginase Injection for intravenous or intramuscular administration
  • MejorAsp ™
    • Offers lower dosing across longer intervals i. e. 2500IU/sq. mt. every 14 days.
    • Offers slower clearance from plasma with lesser half life (6 days), hence lesser allergic reactions.
    • Reduces risk of high titer Antibodies (Abs) formation, hence no loss of enzyme activity.

MejorAsp ™ is manufactured by a US FDA approved biotechnology plant – Certified by WHO-GMP and ISO 9000:2001, Therapeutic Goods Administration, Australia (TGA) and by the European Union’s Certificate Of Suitability (COS).

For more information regarding MejorAsp TM, please contact your local Sales Representative or email us at info@sayretherapeutics.com